All Stories

  1. Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
  2. Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain
  3. Gut Dysbiosis and Its Role in the Anemia of Chronic Kidney Disease
  4. Using Chronic Kidney Disease as a Model Framework to Estimate Healthcare-Related Environmental Impact
  5. Cardiovascular-kidney-metabolic syndrome definition and its role in the prevention, risk staging, and treatment. An opportunity for the Nephrology
  6. La definición del síndrome cardiovascular-reno-metabólico (cardiovascular-kidney-metabolic syndrome) y su papel en la prevención, estatificación del riesgo y tratamiento. Una oportunidad para la Nefrología
  7. Effect of SGLT2 inhibitors on anemia and their possible clinical implications
  8. Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas
  9. Fibrilación auricular no valvular en pacientes en diálisis peritoneal: prevalencia, tratamiento y profesionales implicados
  10. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations
  11. The ERA Registry Annual Report 2021: a summary
  12. Gender-specific risk factors and outcomes of hyperkalemia in CKD patients: smoking as a driver of hyperkalemia in men
  13. 236.2: Simultaneous kidney-pancreas transplantation improves endothelial dysfunction induced by extracellular vesicles
  14. Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N
  15. Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Reply of the Anemia group of the Spanish Society of Nephrology
  16. Epidemiology and treatment of renal anaemia in Spain: RIKAS retrospective study
  17. Epidemiología y tratamiento de la anemia renal en España: estudio retrospectivo RIKAS
  18. Concentración de hemoglobina reticulocitaria y ferroterapia en la enfermedad renal crónica: respuesta del grupo de Anemia de la Sociedad Española de Nefrología
  19. Aspectos no resueltos en el manejo de la anemia renal, un consenso Delphi del Grupo de Anemia de la S.E.N
  20. Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist
  21. Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice
  22. Gout Prevalence, Practice Patterns, and Associations with Outcomes in North American Dialysis Patients
  23. Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo
  24. Impacto pronóstico de la enfermedad renal crónica sobre el cierre percutáneo de la orejuela izquierda en la fibrilación auricular: una experiencia unicéntrica
  25. Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis
  26. Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients
  27. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
  28. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
  29. Iron Deficiency in CKD Without Concomitant Anemia
  30. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review
  31. Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion
  32. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
  33. Aplastic crisis secondary to parvovirus B19 primoinfection as an infrequent cause of anemia in an immunocompetent, non-dialysis chronic kidney disease patient
  34. Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study
  35. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
  36. Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N
  37. Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group
  38. Effect of comorbidities on survival in patients >80 years of age at onset of renal replacement therapy: data from the ERA-EDTA Registry
  39. Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
  40. SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation Results
  41. Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study
  42. Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia
  43. Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease
  44. Data from the ERA-EDTA Registry was examined for trends in excess mortality in European adults on kidney replacement therapy.
  45. Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
  46. Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
  47. Percutaneous Left Atrial Appendage Closure, A Safe Alternative To Anticoagulation For Patients With Non‐Valvular Atrial Fibrillation And End‐Stage Renal Disease On Hemodialysis: A Single Center Experience
  48. Sex Differences in Kidney Replacement Therapy Initiation and Maintenance
  49. Changes in clinical indicators related to the transition from dialysis to kidney transplantation—data from the ERA-EDTA Registry
  50. Vegetable-Based Diets for Chronic Kidney Disease? It Is Time to Reconsider
  51. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients
  52. ¿Son seguros y eficaces los antiagregantes plaquetarios en los pacientes con insuficiencia renal?
  53. Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry
  54. Antioxidant and Anti-Inflammatory Strategies Based on the Potentiation of Glutathione Peroxidase Activity Prevent Endothelial Dysfunction in Chronic Kidney Disease
  55. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology
  56. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  57. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  58. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  59. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia
  60. Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
  61. Insuficiencia cardíaca en la enfermedad renal y déficit de hierro: importancia de la ferroterapia
  62. Heart failure in patients with kidney disease and iron deficiency: The role of iron therapy
  63. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function
  64. TO021DIRECT FACTOR Xa INHIBITOR APIXABAN PREVENTS ENDOTHELIAL ACTIVATION AND DAMAGE ASSOCIATED WITH CHRONIC KIDNEY DISEASE
  65. Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis
  66. Gut microbiota in chronic kidney disease
  67. Enfermedad renal crónica y dislipidemia
  68. Microbiota intestinal en la enfermedad renal crónica
  69. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study
  70. Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study
  71. Consenso Delphi sobre el diagnóstico y manejo de la dislipidemia en pacientes con enfermedad renal crónica: análisis post-hoc del estudio DIANA
  72. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study
  73. Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: estudio Diana
  74. Estudio EPRICS con eritropoyetina: otro intento fallido para evitar el daño renal poscirugía cardiaca
  75. WITHDRAWN: Estudio EPRICS con eritropoyetina: otro intento fallido para evitar el daño renal poscirugía cardiaca
  76. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis
  77. Carotid Atherosclerotic Disease Predicts Cardiovascular Events in Hemodialysis Patients: A Prospective Study
  78. FO020ENDOTHELIAL DYSFUNCTION IN UREMIA: EFFECT OF FLAVONOIDS AND ANTIOXIDANTS
  79. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
  80. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
  81. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
  82. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
  83. TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia
  84. Efficacy of a Simple Dosage Scheme to Convert From Shorter-acting Erythropoiesis-stimulating Agent to Continuous Erythropoietin Receptor Activator in Kidney Transplantation Patients
  85. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study
  86. Sensitivity of Blood Volume Monitoring for Fluid Status Assessment in Hemodialysis Patients
  87. Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia
  88. NFκB in the Development of Endothelial Activation and Damage in Uremia: An In Vitro Approach
  89. Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES
  90. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study
  91. Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative
  92. Endothelial Dysfunction in Chronic Renal Failure
  93. Respuesta
  94. Prevalence of Chronic Kidney Disease in Patients With or at a High Risk of Cardiovascular Disease
  95. Prevalencia de insuficiencia renal crónica en pacientes de alto riesgo o con enfermedad cardiovascular
  96. Response
  97. What Infusion Flow Should Be Used for Mid-Dilution Hemodiafiltration?
  98. Introducción
  99. Abordaje multidisciplinar de la enfermedad aterotrombótica
  100. Conclusiones
  101. Mid-Dilution Hemodiafiltration: A Comparison with Pre- and Postdilution Modes Using the Same Polyphenylene Membrane
  102. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
  103. In Vivo Evaluation of Platelet Activation by Different Cellulosic Membranes
  104. Prevalence and Clinical Characteristics of HIV Type 1-Infected Patients Receiving Dialysis in Spain: Results of a Spanish Survey in 2006: GESIDA 48/05 Study
  105. Influence of the Ionic Dialysance Monitor on Kt Measurement in Hemodialysis
  106. Mspl identifies a biallelic polymorphism in the promoter region of the α2A-adrenergic receptor gene
  107. Differential Expression of Proteins From Cultured Endothelial Cells Exposed to Uremic Versus Normal Serum
  108. Chronic hypotension in hemodialysis patients: role of functional vascular changes and vasodilator agents
  109. Effect of Two Different Dialysis Membranes on Leukocyte Adhesion and Aggregation
  110. Dyslipidemia and the progression of renal disease in chronic renal failure patients
  111. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study
  112. Cigarette smoke concentrate increases 8-epi-PGF2$alpha; and TGF$beta;1 secretion in rat mesangial cells
  113. The effects of smoking and its cessation on 8-epi-PGF2α and transforming growth factor-beta 1 in Type 1 diabetes mellitus
  114. Biocompatibility of Cellulosic and Synthetic Membranes Assessed by Leukocyte Activation
  115. Update in nephrology: Highlights from the 36th Annual Meeting of the ASN
  116. Interactions Between Vasoconstrictors and Vasodilators in Regulating Hemodynamics of Distinct Vascular Beds
  117. Uraemic medium accelerates proliferation but does not induce apoptosis of endothelial cells in culture
  118. Darbepoetin alfa: A novel erythropoiesis-stimulating protein
  119. Nonconvulsive status epilepticus in dialysis patients
  120. Morbimortalidad cardiovascular en la diabetes mellitus tipo 2
  121. Análisis de la frecuencia cardíaca como factor de riesgo asociado a la progresión de la insuficiencia renal crónica
  122. Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro
  123. Effect of angiotensin II receptor blockade on renal disease progression in patients with non‐diabetic chronic renal failure
  124. Hemodynamic and renal effects of acute and progressive nitric oxide synthesis inhibition in anesthetized dogs
  125. Hipermineralocorticismo exógeno como causa de descompensación de una hipertensión esencial previamente controlada
  126. Mecanismos de desarrollo del daño vascular en pacientes en diálisis
  127. Uremic Medium Disturbs the Hemostatic Balance of Cultured Human Endothelial Cells
  128. Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension
  129. Abnormal platelet cytoskeletal assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling
  130. Papel de la adrenomedulina en el control de la presión arterial y la homeostasis del líquido extracelular
  131. Doxazosin in a gastrointestinal therapeutic system formulation
  132. Novel Erythropoiesis Stimulating Protein
  133. Recombinant human erythropoietin treatment in chronic renal failure: Effects on hemostasis and vasculature
  134. β-adrenergic receptor density and function in left ventricular hypertrophy in young essential hypertensives
  135. Smoking increases serum levels of transforming growth factor-beta in diabetic patients
  136. Clinical pharmacology of nebivolol
  137. Erythropoietin Improves Signaling through Tyrosine Phosphorylation in Platelets from Uremic Patients
  138. Lamifiban
  139. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: Association with early improvement in platelet function
  140. Renal Failure in Multiple Myeloma
  141. Platelet-Leukocyte Activation during Hemodialysis Detected with a Monoclonal Antibody to Leukocyte Integrin CD11b
  142. Advances in hypertension management: Update 1998
  143. Autonomic nervous system and adrenergic receptors in chronic hypotensive haemodialysis patients
  144. New Insights Into the Pathophysiology of Renovascular Hypertension
  145. Vasoactive hormones in uraemic patients with chronic hypotension
  146. Correspondence
  147. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases
  148. Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix
  149. Reticulated platelets in uremic patients: Effect of hemodialysis and continuous ambulatory peritoneal dialysis
  150. Effect of antihypertensive treatment on the increased β-adrenoceptor density in patients with essential hypertension
  151. Reversible Decrease of Surface ß2-Adrenoceptor Number and Response in Lymphocytes of Patients with Pheochromocytoma
  152. 24 Effect of antihypertensive treatment on increased (??2-adrenoceptor density in patients with essential hypertension
  153. 31 Decreased ??2-adrenoceptor number and responsiveness in patients with phaeochromocytoma
  154. Intracellular calcium mobilization and activation of the Na+/H+exchanger in platelets
  155. Minimal-Change Glomerulopathy and Carcinoma
  156. Recombinant human erythropoietin treatment improves platelet function in uremic patients
  157. Calciphylaxis in a Hemodialysis Patient: Appearance After Parathyroidectomy During a Psoriatic Flare
  158. Arginine Vasopressin Infusion Increases Plasma Levels of Atrial Natriuretic Factor in Humans
  159. Lymphocyte surface beta2-adrenoceptors in essential hypertension
  160. Lymphocyte surface beta2-adrenoceptors in essential hypertension
  161. Tumor Markers in Chronic Renal Failure and Hemodialysis Patients
  162. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa
  163. Ocular and Auditory Toxicity in Hemodialyzed Patients Receiving Desferrioxamine
  164. Lymphocyte β2-Adrenergic Receptors in Essential Hypertension: Studies in Basal Conditions and After Dynamic Exercise
  165. Treatment of Hyperkalaemia in Renal Failure: Salbutamol v. Insulin
  166. Improvement of renal function in azotaemic hypertensive patients after surgical revascularization
  167. Reversal of Renal Failure after Revascularization in Atheromatous Renovascular Disease
  168. A Possible Pathogenic Mechanism for Rhabdomyolysis Associated with Multiple Myeloma
  169. Visceral Involvement of Dialysis Amyloidosis
  170. Thoracic Duct Injury: An Unusual Complication following Subclavian Catheterization for Hemodialysis
  171. UREMIC PLASMA, AFTER INFUSION OF DESMOPRESSIN, IMPROVES THE INTERACTION OF NORMAL PLATELETS WITH VESSEL SUBENDOTHELIUM
  172. Rhabdomyolysis Associated With Pleural Tuberculosis
  173. NIFEDIPINE-INDUCED PAROTITIS